<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821674</url>
  </required_header>
  <id_info>
    <org_study_id>DS5670-A-J101</org_study_id>
    <secondary_id>jRCT2071200110</secondary_id>
    <nct_id>NCT04821674</nct_id>
  </id_info>
  <brief_title>Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects</brief_title>
  <official_title>A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and immunogenicity of DS-5670a (COVID-19&#xD;
      Vaccine) and determine the recommended dose in Japanese healthy adults and elderly&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 up to Day 57 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Local and Systemic Adverse Events</measure>
    <time_frame>Day 1 up to Day 14 post-first and second dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Serious Events</measure>
    <time_frame>Day 1 up to 12 months post-second dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific Neutralizing Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Rates of SARS-CoV-2 Specific Neutralizing Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of anti-IgG Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of anti-IgG Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rates of anti-IgG Antibody</measure>
    <time_frame>Days 15, 29, 43, and 57 post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Maximum (Peak) Observed Plasma Concentration (Cmax) Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>Cmax of plasma MAFB-7566a and constituent lipids of lipid nanoparticle (LNP) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Time to Reach Maximum Concentration (Tmax) Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>Tmax of plasma MAFB-7566a and constituent lipids of LNP will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Area Under the Concentration-time Curve Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>Area under the concentration-time curve from time 0 to last measurable time point (AUClast) and time 0 to infinity (AUCinf) of plasma MAFB-7566a and constituent lipids of LNP will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Apparent Total Body Clearance (CL/F) Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>CL/F of plasma MAFB-7566a and constituent lipids of LNP will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Terminal Elimination Half-life (t1/2) Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>Half-life (t1/2) of plasma MAFB-7566a and constituent lipids of LNP will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter of Apparent Volume of Distribution (Vz/F) Following Intramuscular Injection of DS-5670a</measure>
    <time_frame>Days 1, 2, 4, 8, 15, 29, 30, 32, 36, 43, and 57 post-dose</time_frame>
    <description>Vz/F of plasma MAFB-7566a and constituent lipids of LNP will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Cohort A1: DS-5670a 10 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: DS-5670a 30 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: DS-5670a 60 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: DS-5670a 100 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy adults participants will be randomized to receive a intramuscular injection of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1: DS-5670a 10 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2: DS-5670a 30 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3: DS-5670a 60 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B4: DS-5670a 100 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DS-5670a</intervention_name>
    <description>DS-5670a (10, 30, 60 or 100 µg) administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total</description>
    <arm_group_label>Cohort A1: DS-5670a 10 µg</arm_group_label>
    <arm_group_label>Cohort A2: DS-5670a 30 µg</arm_group_label>
    <arm_group_label>Cohort A3: DS-5670a 60 µg</arm_group_label>
    <arm_group_label>Cohort A4: DS-5670a 100 µg</arm_group_label>
    <arm_group_label>Cohort B1: DS-5670a 10 µg</arm_group_label>
    <arm_group_label>Cohort B2: DS-5670a 30 µg</arm_group_label>
    <arm_group_label>Cohort B3: DS-5670a 60 µg</arm_group_label>
    <arm_group_label>Cohort B4: DS-5670a 100 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as an intramuscular injection into the deltoid muscle of the upper arm; 2 injections total</description>
    <arm_group_label>Cohort A: Placebo</arm_group_label>
    <arm_group_label>Cohort B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese citizen&#xD;
&#xD;
          -  Healthy adults aged ≥20 and &lt;65 years, or healthy elderly aged ≥65 and &lt;75 years (at&#xD;
             the time of informed consent)&#xD;
&#xD;
          -  Body Mass Index (BMI) is ≥17.5 and &lt;30.0 kg/m^2 (at screening)&#xD;
&#xD;
          -  Participants who can follow the compliance requirements during clinical trials,&#xD;
             undergo medical examinations and tests specified by the protocol, and report symptoms,&#xD;
             etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of immunodeficiency or having a close relative with congenital&#xD;
             immunodeficiency.&#xD;
&#xD;
          -  Have a history of SARS-CoV-2 infection.&#xD;
&#xD;
          -  Have previously participated in an investigational study of SARS-Cov-2 vaccine or&#xD;
             involving LNPs.&#xD;
&#xD;
          -  Have a history of anaphylaxis or severe allergies due to food, cosmetics, medicines,&#xD;
             or vaccination&#xD;
&#xD;
          -  Have alcohol or drug dependence.&#xD;
&#xD;
          -  Have a fever of ≥39.0°C or symptoms of suspected allergies such as systemic rash&#xD;
             within 2 days after past vaccination, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>+81-3-6225-1111(M-F 9-5 JST)</phone>
    <email>dsclinicaltrial@daiichisankyo.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>SOUSEIKAI Hakata Clinic</name>
      <address>
        <city>Hakata</city>
        <state>Fukuoka</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 Prevention</keyword>
  <keyword>SARS CoV-2</keyword>
  <keyword>Coronavirus Vaccine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

